ProCE Banner Activity

CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC

Slideset Download
Conference Coverage
With an extended follow-up of approximately 5 years, durable clinical benefit with no new safety concerns was observed with nivolumab ± ipilimumab for patients with MSI-H/dMMR metastatic CRC.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab